DS
PRCT icon

David Shaw’s Procept Biorobotics PRCT Stock Holding History

David Shaw’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,300
Closed -$387K – 4950
2025
Q4 		$387K Buy
12,300
+3,900
+46% +$129K ﹤0.01% 4043
2025
Q3 		$300K Buy
+8,400
New +$384K ﹤0.01% 4110

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

David Shaw's PRCT Position: Q3 2025 in Review

David Shaw sold out of Procept Biorobotics (PRCT) in Q3 2025, closing a stake of 73,662 shares — an estimated $3.36M sold.

David Shaw first reported a position in PRCT in Q4 2021 and held it in 12 quarters. The position peaked at $48.9M in Q4 2024. 242 funds tracked by Wall St. Rank hold PRCT as of Q3 2025.

  • David Shaw reported no remaining Procept Biorobotics position as of Q3 2025 after selling out during the quarter.
  • David Shaw sold 73,662 Procept Biorobotics shares in Q3 2025, an estimated $3.36M.
  • David Shaw first reported a position in Procept Biorobotics in Q4 2021 and held it in 12 quarters.
  • David Shaw's Procept Biorobotics position peaked at $48.9M in Q4 2024.
  • 242 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2025.

Based on D.E. Shaw & Co's 13F filing for Q3 2025, filed 14 Nov 2025.